Q3 2025 EPS Estimates for Novartis AG (NYSE:NVS) Decreased by Analyst

Novartis AG (NYSE:NVS) – Zacks Research reduced their Q3 2025 earnings estimates for Novartis in a note issued to investors on Monday, April 22nd. Zacks Research analyst E. Bagri now anticipates that the company will post earnings of $1.98 per share for the quarter, down from their prior forecast of $1.99. The consensus estimate for Novartis’ current full-year earnings is $7.13 per share.

Several other analysts have also recently weighed in on the stock. Morgan Stanley initiated coverage on shares of Novartis in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $114.00 price objective on the stock. BMO Capital Markets upped their target price on shares of Novartis from $114.00 to $116.00 and gave the stock a “market perform” rating in a research report on Wednesday. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $115.00.

Novartis Price Performance

Shares of Novartis stock opened at $98.35 on Wednesday. The company has a current ratio of 1.15, a quick ratio of 0.93 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $201.03 billion, a price-to-earnings ratio of 13.70, a P/E/G ratio of 1.55 and a beta of 0.54. Novartis has a 1-year low of $92.19 and a 1-year high of $108.78. The firm’s 50-day moving average price is $97.93 and its two-hundred day moving average price is $98.99.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, January 30th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). The firm had revenue of $11.42 billion for the quarter, compared to the consensus estimate of $11.69 billion. Novartis had a return on equity of 29.90% and a net margin of 29.83%. During the same period in the prior year, the company posted $1.51 earnings per share.

Hedge Funds Weigh In On Novartis

A number of large investors have recently modified their holdings of the stock. Frazier Financial Advisors LLC acquired a new position in Novartis in the fourth quarter valued at approximately $26,000. Private Ocean LLC acquired a new position in Novartis in the first quarter valued at approximately $25,000. Richardson Financial Services Inc. acquired a new position in Novartis in the fourth quarter valued at approximately $26,000. Operose Advisors LLC acquired a new position in Novartis in the third quarter valued at approximately $28,000. Finally, Planned Solutions Inc. acquired a new position in Novartis in the fourth quarter valued at approximately $31,000. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Novartis Increases Dividend

The business also recently announced an annual dividend, which was paid on Thursday, March 7th. Stockholders of record on Friday, March 8th were given a dividend of $3.7772 per share. This represents a dividend yield of 3.1%. This is a positive change from Novartis’s previous annual dividend of $3.47. The ex-dividend date was Thursday, March 7th. Novartis’s dividend payout ratio is presently 33.84%.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.